Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 403

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Sterile protection against human malaria by chemoattenuated PfSPZ vaccine

Open access
Mordmüller, Benjamin, Surat, Güzin, Lagler, Heimo, Chakravarty, Sumana, Ishizuka, Andrew S., Lalremruata, Albert, Gmeiner, Markus, Campo, Joseph J., Esen, Meral, Ruben, Adam J., Held, Jana, Calle, Carlos Lamsfus, Mengue, Juliana B., Gebru, Tamirat, Ibáñez, Javier, Sulyok, Mihály, James, Eric R., Billingsley, Peter F., Natasha, KC, Manoj, Anita, Murshedkar, Tooba, Gunasekera, Anusha, Eappen, Abraham G., Li, Tao, Stafford, Richard E., Li, Minglin, Felgner, Phil L., Seder, Robert A., Richie, Thomas L., Sim, B. Kim Lee, Hoffman, Stephen L., Kremsner, Peter G.·2017·Nature

Abstract

A highly protective malaria vaccine would greatly facilitate the prevention and elimination of malaria and containment of drug-resistant parasites. A high level (more than 90%) of protection against malaria in humans has previously been achieved only by immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (PfSPZ) inoculated by mosquitoes; by intravenous injection of aseptic, purified, radiation-attenuated, cryopreserved PfSPZ (‘PfSPZ Vaccine’); or by infectious PfSPZ inoculated by mosquitoes to volunteers taking chloroquine or mefloquine (chemoprophylaxis with sporozoites). We assessed immunization by direct venous inoculation of aseptic, purified, cryopreserved, non-irradiated PfSPZ (‘PfSPZ Challenge’) to malaria-naive, healthy adult volunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac). Three doses of 5.12 × 104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria infection ten weeks after the last dose (group III). Protective efficacy was dependent on dose and regimen. Immunization with 3.2 × 103 (group I) or 1.28 × 104 (group II) PfSPZ protected 3 out of 9 (33%) or 6 out of 9 (67%) volunteers, respectively. Three doses of 5.12 × 104 PfSPZ at five-day intervals protected 5 out of 8 (63%) volunteers. The frequency of Pf-specific polyfunctional CD4 memory T cells was associated with protection. On a 7,455 peptide Pf proteome array, immune sera from at least 5 out of 9 group III vaccinees recognized each of 22 proteins. PfSPZ-CVac is a highly efficacious vaccine candidate; when we are able to optimize the immunization regimen (dose, interval between doses, and drug partner), this vaccine could be used for combination mass drug administration and a mass vaccination program approach to eliminate malaria from geographically defined areas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature21060

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 403

Metadata

Authors
Mordmüller, B., Surat, G., Lagler, H., Chakravarty, S., Ishizuka, A. S., Lalremruata, A., Gmeiner, M., Campo, J. J., Esen, M., Ruben, A. J., Held, J., Calle, C. L., Mengue, J. B., Gebru, T., Ibáñez, J., Sulyok, M., James, E. R., Billingsley, P. F., Natasha, K., Manoj, A., Murshedkar, T., Gunasekera, A., Eappen, A. G., Li, T., Stafford, R. E., Li, M., Felgner, P. L., Seder, R. A., Richie, T. L., Sim, B. K. L., Hoffman, S. L., & Kremsner, P. G.
Venue
Nature
Published
2017-02
Volume
542
Issue
7642
Pages
445-449
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2588256621
Cited by
403
References
36
FWCI
46.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. https://app.cochat.ai/papers/10.1038/nature21060
The paper
Mordmüller, B., Surat, G., Lagler, H., Chakravarty, S., Ishizuka, A. S., Lalremruata, A., Gmeiner, M., Campo, J. J., Esen, M., Ruben, A. J., Held, J., Calle, C. L., Mengue, J. B., Gebru, T., Ibáñez, J., Sulyok, M., James, E. R., Billingsley, P. F., Natasha, K., . . . Kremsner, P. G. (2017). Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. https://doi.org/10.1038/nature21060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.